Antitrust Chronicle

2006 - 2012

from Competition Policy International
Series data maintained by Lindsay McSweeney ().

Access Statistics for this journal.
Track citations for all items by RSS feed
Is something missing from the series or not right? See the RePEc data check for the archive and series.

2012, volume 10

Has the Administrative Court’s Reversal of the IAA Decision in Pfizer Got It Right?

Daniela Ampollini

Education Before Enforcement? Key Insights From Australian Cartel Research

Caron Beaton-Wells and Christine Parker

How the FTC Could Beat Google

Robert Lande and Jonathan Rubin

Merger Control in India

R. Shyam Khemani, Cyril Shroff and Nisha Kaur Uberoi

Shop 'Til You Drop: Retail Mergers and the U.K. Competition Review Process

Richard Blewett

The FCC’s Unstructured Role in Transactions

Larry Downes and Geoffrey A. Manne

Deal Makers Beware: Recent Trends in U.S. Merger Enforcement

Daniel Hemli and Jacqueline Java

2012, volume 9

Innovation is King. Or is it?

Paul Lugard and David Cardwell

Fines for Abuse of Dominance in “High Tech†Markets

Benoit Durand and Andreas Reindl

Antitrust Concerns of Patent Acquisitions

Ilene Knable Gotts and Scott Sher

Competition, Standards, and Patents

Per Hellstrom and Thomas Kramler

Generic Drugmakers Will Challenge Patents Even When They Have a 97% Chance of Losing: The FTC Report that K-Dur Ignored

Kelly Smith and Jonathan Gleklen

"From Astra-Zeneca to Pfizer" Stage II: The Italian Administrative Court Reverses the Monopolization Claim Established by the AutoritàGarante della Concorrenza e del Mercato

Stefano Grassani

The Role of Keyword Advertising in Competition Among Rival Brands

David S. Evans and Elisa Mariscal

A Short Note on Plea Agreements in Canadian Antitrust Cases

Graham Reynolds

The Canadian “Sir†Process: A Progress Report

Mark Katz and Erika Douglas

Canadian Competition Tribunal Orders Divestiture in Waste Merger: Some Lessons Learned

Richard Elliott

The Constitutionality of Administrative Monetary Penalties Under the Competition Act: Is Rowan a Full Answer?

John Campion and Antonio Di Domenico

Competition Law Guidance Under Commissioner Aitken: A Survey

Kevin Ackhurst

2012, volume 8

Towards a Competition Cultureâ€â€Advocacy and Outreach in the South African Competition Regime

Trudi Makhaya

Effective Engagement of Stakeholders: Inquire, Innovate, Intrigue

The Competition Commission of Singapore

Competition Advocacy in Mexico: Lessons From the Past Decade

Angel Lopez Hoher

Outreach Activities of the JFTC

The Japan Fair Trade Commission

Competition Outreach and Advocacy When All the World Is Your Stage: The ICN Experience

Maria Coppola

From Post- to Pre-Merger Notification: The Ultimate Outreach Challenge

Carlos Ragazzo and Cristiane Landerdahl de Albuquerque

Reach Out to a Wide Audience

Taiwan Fair Trade Commission

Ten Years of Pros and Cons Conferences

Arvid Fredenberg

Positioning Competition Policy in Chile: Outreach, Advocacy, and Alternative Dispute Resolution Mechanisms

Mario Ybar and Fernando Araya

Enforcement “Plus:†The FTC’s Business Education Efforts

Kelly Signs

Competition Advocacy at the Federal Trade Commission: Recent Developments Build on Past Successes

Tara Isa Koslov

2012, volume 7

Abuse of Regulatory Procedures in the Pharmaceutical Sectorâ€â€Developments Since the General Court’s Judgment in AstraZeneca

Kristina Nordlander and Patrick Harrison

European Commission Enforcement in the Pharmaceutical Sector: Less Than Expected? The Boehringer Case Closure Suggests As Much

Sean-Paul Brankin

From Astra-Zeneca to Pfizer: When Protection of Originators’ Patents Ceases to be a “Right†and Becomes an Abuse of Dominance

Stefano Grassani

Rules on Retailer-Supplier Relationships in the Competition Policy of the Russian Federation: How and Why Misunderstanding Economics Threatens the Competitiveness of the Sector

Svetlana Avdasheva and Andrey Shastitko

The Extraterritorial Effect of Antimonopoly Law

Kai Zhang

Why a Reduction in Health Care Costs Per Se May be a Misleading Policy Objective

Rosa Abrantes-Metz

Pharmaceutical Patents, Settlements, “Reverse Payments,†and Exclusion: Update

John Bigelow

Looking for Sense in the Italian Antitrust Authority Decision in the Pfizer Xalatan Case

Daniela Ampollini

Why and How Should the Libor Be Reformed?

Rosa Abrantes-Metz

Healthcare Reform and Antitrust Enforcement: Provider Consolidation Encouraged, Scrutinized

Jane Willis, Melissa Davenport and Ryan McManus

Between the ACA and Antitrust Enforcers: A Rock and a Hard Place or an Opportunity?

Toby Singer and David Pearl

The Changing Health Care Sector: Tough New Challenges for Antitrust Enforcers

Robert Leibenluft

Health Care Reform, Provider Affiliations, and Antitrust Risks

Lona Fowdur and John Gale

When the Antitrust Laws May Not Allow Healthcare Providers to Pursue Merger-Specific Efficiencies – And What Healthcare Providers Can Do About It

Ashley Fischer, Jeffrey Brennan and David Marx

2012, volume 6

Federal Trade Commission Suffers Another Setback in Its Campaign to End Pharmaceutical Reverse-Settlement Agreements

Aidan Synnott and William Michael

Eleventh Circuit Rejects the Strength of a Patent as a Criterion for the Legality of Reverse-Payment Settlements

William Rooney and Jodi Lucena-Pichardo

Federal Trade Commission Rejected in “Reverse Payment†Suit

Kevin Noonan

Reverse Payment Settlements: Presumptively Bad or Usually Acceptable?

Kyle Musgrove and Richard Ripley

Cervantes’ Sequel: The FTC’s Quest to End Pay-for-Delay Pharma Settlements

Anne Layne-Farrar

Pharmaceutical Patents, Settlements, Reverse Payments, and Exclusion

John Bigelow

The eBooks Case: A Canadian Perspective

Steve Szentesi and Mark Katz

Should the e-Book Case Presage the Decline of The Per Se and Market Share Doctrines?

Steven Semeraro

United States v. Apple and the Contemporary Legitimacy of Antitrust

Chris Sagers

New Toys For Old Games: eBooks – iTroubles

Jay Himes and Meegan Hollywood